On The Road And Through The Window: Inside Three Biotech IPOs
This article was originally published in Start Up
Executive Summary
Ophthotech, OncoMed, and bluebird bio are three of the dozens of biotechs that have made public debuts this year. Here’s how they did it, and the decisions they made to take advantage of being in the right place at the right time.
You may also be interested in...
Royalty Rights To AMD Drug Spur $175 Million Capital Raise For Ophthotech
Money will finance 1,900-patient, 200-site Phase III trial for wet AMD drug Fovista, expected to work in concert with anti-VEGF therapies such as Lucentis to restore eye function. The transaction is just the latest ophthalmology financing involving Novo AS, SV Life Sciences and executives once with Eyetech.
From Public To Private, Crossover Investors Are Back In Biotech
Armed with cash from a robust M&A and a stock market boom, mutual and hedge funds are eagerly crossing over into mezzanine rounds for private biotechs and playing key roles in some of the year’s biggest venture financings.
JOBS Gets To Work On IPOs, Companies Cherry Pick Benefits
The JOBS Act has made it easier for life sciences companies to file to go public and to communicate with potential investors. But the cost savings from reduced regulatory compliance has yet to be fully achieved.